Sartorius
Sartorius AG, a leading global partner of the biopharmaceutical industry, is headquartered in Göttingen, Germany. Founded in 1870, the company has evolved significantly, establishing a strong presence in Europe, North America, and Asia. Sartorius operates primarily in the life sciences and laboratory equipment sectors, focusing on bioprocess solutions and laboratory instruments. The company is renowned for its innovative products, including high-precision balances, bioreactors, and filtration systems, which are designed to enhance productivity and ensure quality in biopharmaceutical manufacturing. Sartorius has achieved notable milestones, such as its commitment to sustainability and digital transformation, positioning itself as a market leader. With a strong emphasis on research and development, Sartorius continues to drive advancements in the industry, making it a trusted name among scientists and manufacturers worldwide.
DitchCarbon Score
How does Sartorius's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sartorius's score of 52 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sartorius's reported carbon emissions
In 2023, Sartorius reported total carbon emissions of approximately 896,898,000 kg CO2e, comprising 13,103,000 kg CO2e from Scope 1, 26,823,000 kg CO2e from Scope 2, and a significant 856,972,000 kg CO2e from Scope 3 emissions. This marked an increase from previous years, with total emissions in 2022 at about 1,137,703,000 kg CO2e. Sartorius has set ambitious climate commitments, aiming for net climate neutrality by 2045. Additionally, the company has established a near-term target to reduce CO2 equivalent emission intensity by an average of 10% per year from 2019 levels by 2030. This commitment encompasses all scopes of emissions, reflecting a comprehensive approach to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The company’s emissions data highlights a growing trend, necessitating robust strategies to meet its reduction targets and achieve long-term climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 7,738,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,018,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sartorius is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
